Double-Blind, Placebo-Controlled, Multicenter, Randomized, Phase IIB Neoadjuvant Study of Letrozole-Lapatinib in Postmenopausal Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative, Operable Breast Cancer
Valentina Guarneri(Istituto Oncologico Veneto), PierFranco Conte(University of Padua), Antonino Maiorana(University of Modena and Reggio Emilia), Fabrizio Artioli(Roche (Switzerland)), Daniele Generali(University of Trieste), Alberto Bottini(University of Genoa), Catherine Ellis(GlaxoSmithKline (United States)), Ramona F. Swaby(Merck & Co., Inc., Rahway, NJ, USA (United States)), C. Boni(Ospedale Santa Maria), Giancarlo Bisagni, Guido Ficarra(University of Modena and Reggio Emilia), Antonio Frassoldati(Italian Oncology Group of Clinical Research), C. Holford(Istituti Ospitalieri di Cremona), Luigi Cavanna(University of Pavia), Stefania Bettelli(University of Modena and Reggio Emilia), Enrico Tagliafico(University of Modena and Reggio Emilia), Simona Nuzzo(Istituti Ospitalieri di Cremona), Federico Piacentini(Azienda Unita' Sanitaria Locale Di Modena), Enrica Roncaglia(University of Modena and Reggio Emilia)
Cited by 62
Related Papers
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
|Journal of Clinical Oncology|2000|2.3k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
|IRIS UNIMORE (University of Modena and Reggio Emilia)|2005|1.6k
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
|New England Journal of Medicine|2014|1.1k